Healthcare IT

Business

Chemed's Stock Slump Sparks Valuation Debate: Undervalued Opportunity or Warning Sign?

Chemed Corporation (NYSE: CHE) has seen its share price soften recently, reigniting investor debate over whether the healthcare services provider is now undervalued. With the stock trading around $430, a significant gap exists against some fair value estimates, even as operational challenges in its VITAS and Roto-Rooter segments loom.

Jan 30, 2026

World

Federal Judge Dismisses Key Charges in UnitedHealth CEO Murder Case

A New York federal judge has dismissed murder and weapons charges against Luigi Mangione, the man accused of killing UnitedHealthcare's CEO. The ruling deals a significant setback to federal prosecutors and removes the possibility of a death penalty in the high-profile case.

Jan 30, 2026

Business

OSI Systems Beats Expectations, Raises Outlook Despite Sector Headwinds

OSI Systems posts record Q2 revenue and lifts full-year EPS guidance, navigating softness in security bookings and healthcare challenges with optimism for a stronger second half.

Jan 30, 2026

Business

SAP Shifts Healthcare Strategy, Appoints New North America Chief Amid Market Scrutiny

SAP discontinues its legacy IS-H healthcare software in the DACH region, impacting dozens of hospitals, while appointing David Robinson to lead its crucial North American operations. The moves signal a strategic pivot as the enterprise software giant navigates a complex market landscape.

Jan 30, 2026

Business

Beyond the Penny Stock Label: Three Asian Equities Showing Financial Resilience

In a volatile market, certain low-priced Asian stocks are drawing attention not just for their valuation, but for underlying financial strength. We examine three such companies—from healthcare in New Zealand to property services in Greater China—that defy the typical 'penny stock' stereotype with solid fundamentals.

Jan 30, 2026

Business

Navigating Market Volatility: Three ASX Penny Stocks With Potential for February 2026

As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.

Feb 2, 2026

World

MSF Refuses Israeli Demand for Staff Data, Citing Safety Risks in Gaza

Doctors Without Borders (MSF) has definitively rejected an Israeli order to hand over sensitive staff information, following months of failed negotiations. The move comes amid a wider crackdown on aid groups and a devastating toll on healthcare workers in the conflict.

Jan 30, 2026

Business

C3.ai Remains a Lightning Rod in AI Investment Debate Amid Capital Concerns

While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.

Feb 2, 2026

Business

Gymshark Founder Ben Francis on Billionaire Status: 'It's Just a Number on Paper'

From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.

Feb 2, 2026

Business

Analysts See Long-Term Promise in Legend Biotech's Carvykti Despite Fourth-Quarter Sales Shortfall

While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.

Feb 2, 2026

Business

Apis Flagship Fund Outperforms in Q4 2025, Cites Stock Picks and Strategy

The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).

Feb 2, 2026

Business

Celcuity's Precision Oncology Push Catches Eye of Top-Performing Fund Apis Capital

Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

Wisconsin Labor Market Shows Resilience Despite January Layoffs Affecting 366 Workers

Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.

Feb 2, 2026

Business

Palantir's AI Software Growth Exceeds 25% Annually, Phillip Securities Sees Major Upside with $208 Target

Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.

Feb 2, 2026

Business

IBM Bolsters Enterprise AI Strategy with New Platform, Key Partnership, and PepsiCo CEO Joining Board

IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.

Feb 2, 2026

World

Former Peruvian Foreign Minister Dies in Brazilian Prison Hospital While Awaiting Extradition

Augusto Blacker Miller, a controversial figure from Peru's Fujimori era, has died in a Rio de Janeiro prison hospital. The 80-year-old, arrested in Brazil last December on an Interpol warrant, succumbed to cardiorespiratory arrest, reigniting debates about justice, aging detainees, and cross-border legal accountability.

Feb 2, 2026

Business

Sanofi's Pipeline Gains Momentum with Key Phase 3 Successes in Rare Disease and Immunology

Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.

Feb 2, 2026

Business

Medicare's Obesity Drug Coverage Set to Fuel Lilly's Weight-Loss Pill Launch, CEO Says

Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.

Feb 2, 2026